Drug
Sunitinib clinical trials
Also written Sutent, SU011248 and SU11248.
Includes 1 study of Sunitinib maleate.
- studies test it
- 340
- open now
- 13
- in phase 3
- 19
- first study started
- 2003
Keep track of what changes. Save the Sunitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Sutent
- 150
Combined with it in one product
Studies by the year they started
340 studies that test it; most in 2007 (71)
| Year | Studies |
|---|---|
| 2003 | 3 |
| 2004 | 6 |
| 2005 | 13 |
| 2006 | 44 |
| 2007 | 71 |
| 2008 | 53 |
| 2009 | 41 |
| 2010 | 17 |
| 2011 | 12 |
| 2012 | 15 |
| 2013 | 8 |
| 2014 | 7 |
| 2015 | 9 |
| 2016 | 8 |
| 2017 | 10 |
| 2018 | 6 |
| 2019 | 7 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 87
- Phase 2
- 237
- Phase 3
- 19
- Phase 4
- 8
- No phase
- 16
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 10
Who runs them
Industry 87 · Other 253
Pfizer (60) · National Cancer Institute (NCI) (40) · M.D. Anderson Cancer Center (11) · Memorial Sloan Kettering Cancer Center (10) · Amsterdam UMC, location VUmc (6) · Case Comprehensive Cancer Center (6) · Massachusetts General Hospital (6) · University Health Network, Toronto (5)
Often tested with
Tested in the same studies.
Erlotinib (12) · Gemcitabine (11) · Bevacizumab (10) · Cisplatin (10) · Sorafenib (9) · Pazopanib (9) · Everolimus (9) · Nivolumab (8)
Studies
Open first, then newest update. How each study uses Sunitinib is read from its arms, and is right about nine times in ten.
Testing it · 340
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTRecruitingPhase 2University of MiamiNCT05366816Written as Sunitinib
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT05687123Written as Sunitinib Malate
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Sunitinib
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535Written as Sunitinib (CLOSED TO ENROLLMENT)
- Losartan + Sunitinib in Treatment of OsteosarcomaRecruitingPhase 1University of Colorado, DenverNCT03900793Written as Sunitinib
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as Sunitinib
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingPhase 1/23D Medicines (Sichuan) Co., Ltd.NCT05024214Written as Sunitinib
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07477457Written as Sunitinib
- Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid TumorsRecruitingPhase 1/2Rabin Medical CenterNCT06940349Written as Sunitinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Sunitinib
- OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingPhase 4University Medical Center GroningenNCT05949424Written as Sunitinib
- Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant TreatmentNot yet recruitingNot applicableFirst Affiliated Hospital, Sun Yat-Sen UniversityNCT06032728Written as Sunitinib
- A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant TreatmentNot yet recruitingNot applicableFirst Affiliated Hospital, Sun Yat-Sen UniversityNCT02688491Written as sunitinib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Sunitinib Malate
- Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal MelanomaActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityNCT02068586Written as Sunitinib
- Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)TerminatedPhase 2Association of Urologic Oncology (AUO)NCT01216371Written as Sunitinib
- A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare TumoursActive, not recruitingPhase 2Canadian Cancer Trials GroupNCT01396408Written as Sunitinib
- Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic CancerActive, not recruitingPhase 2Dwight OwenNCT03463460Written as Sunitinib Malate
- Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06390826Written as Sunitinib
- Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell CarcinomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03541902Written as Sunitinib Malate
See all 340 studies that test Sunitinib →
Given in every arm · 23 — Sunitinib is usual care beside what is tested
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsRecruitingPhase 3Cogent Biosciences, Inc.NCT05208047Written as Sunitinib
- Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone SarcomasCompletedPhase 1/2Grupo Espanol de Investigacion en SarcomasNCT03277924Written as Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]
- A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced CancerCompletedPhase 1Sumitomo Pharma America, Inc.NCT02483247Written as Sunitinib
- Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By SurgeryCompletedPhase 2ECOG-ACRIN Cancer Research GroupNCT01164228Written as Sunitinib
- Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell CarcinomaTerminatedPhase 1Ludwig Institute for Cancer ResearchNCT00520533Written as Sunitinib malate
- Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)CompletedPhase 2MendusNCT02432846Written as Sunitinib
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedPhase 1OHSU Knight Cancer InstituteNCT02779283Written as Sunitinib Malate
- Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast CancerTerminatedPhase 1/2University of California, San FranciscoNCT00616122Written as sunitinib malate
- A Study for Participants With Metastatic Renal Cell CarcinomaCompletedPhase 2Eli Lilly and CompanyNCT00709995Written as Sunitinib
- A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell CarcinomaTerminatedPhase 2Eli Lilly and CompanyNCT01391130Written as Sunitinib
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung CancerWithdrawnPhase 2Masonic Cancer Center, University of MinnesotaNCT00748163Written as sunitinib malate
- IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell CarcinomaCompletedPhase 3Immatics Biotechnologies GmbHNCT01265901Written as Sunitinib
- Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00499135Written as Sunitinib Malate
- Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney CancerCompletedPhase 2OHSU Knight Cancer InstituteNCT00425386Written as sunitinib malate
- Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II TrialStatus unknownPhase 1/2Consorzio OncotechNCT02446795Written as Sunitinib
- Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal CancerTerminatedPhase 1Roswell Park Cancer InstituteNCT00524186Written as sunitinib malate
- Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric CancerCompletedPhase 1PfizerNCT00555620Written as sunitinib malate
- Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 PositiveCompletedPhase 1PfizerNCT00372424Written as Sunitinib
- The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer PatientsCompletedPhase 1Leiden University Medical CenterNCT01743300Written as Sunitinib
- Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid TumorCompletedPhase 1M.D. Anderson Cancer CenterNCT00495872Written as Sunitinib
Showing 20 of 23.
As the comparator · 39 — what is tested is compared with Sunitinib
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05773274Written as Sunitinib
- A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyRecruitingPhase 3GlaxoSmithKlineNCT07218926Written as Sunitinib
- A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKINot yet recruitingPhase 3Peking University Cancer Hospital & InstituteNCT07165418Written as Sunitinib
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingPhase 3Hoffmann-La RocheNCT03768063Written as Sunitinib
- Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingPhase 3AstraZenecaNCT05043090Written as sunitinib
- Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell CarcinomaActive, not recruitingPhase 3Sun Yat-sen UniversityNCT07881900Written as Sunitinib
- A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibActive, not recruitingPhase 3Deciphera Pharmaceuticals, LLCNCT03673501Written as Sunitinib
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingPhase 3RayzeBio, Inc.NCT05477576Written as Sunitinib
- A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedPhase 3Bristol-Myers SquibbNCT03141177Written as Sunitinib
- Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaActive, not recruitingPhase 3ExelixisNCT05678673Written as Sunitinib Malate
- Savolitinib vs. Sunitinib in MET-driven PRCC.Active, not recruitingPhase 3AstraZenecaNCT03091192Written as Sunitinib
- Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)CompletedPhase 3Bristol-Myers SquibbNCT02231749Written as Sunitinib
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)CompletedPhase 3Incyte CorporationNCT03260894Written as Sunitinib
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedPhase 2Zai Lab (Shanghai) Co., Ltd.NCT04633122Written as Sunitinib
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaActive, not recruitingPhase 3Eisai Inc.NCT02811861Written as Sunitinib
- Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)CompletedPhase 3Merck Sharp & Dohme LLCNCT02853331Written as Sunitinib
- A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With ImatinibActive, not recruitingPhase 3Deciphera Pharmaceuticals, LLCNCT05734105Written as Sunitinib
- Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell CancerCompletedPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT04394975Written as sunitinib
- A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)CompletedPhase 3PfizerNCT02684006Written as Sunitinib
- Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase IICompletedPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT02230176Written as Sunitinib
Showing 20 of 39.
Codes
What other systems call Sunitinib · ClinicalTrials.gg INT006665
- MeSH (NLM) D000077210SunitinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) V99T50803MSUNITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 357977Confirmed FDA, Wikidata
- Wikidata Q417542sunitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71622SunitinibOne source FDA
- DrugBank DB01268One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077210 | Sunitinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | V99T50803M | SUNITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 357977 | — | Confirmed FDA, Wikidata |
| Wikidata | Q417542 | sunitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71622 | Sunitinib | One source FDA |
| DrugBank | DB01268 | — | One source Wikidata |
Also registered as sunitinib malate (UNII LVX8N1UT73 · RxNorm 616275).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.